Santhera Secures Agreement with Biomedica for the Distribution of AGAMREE® (Vamorolone) in Russia [Yahoo! Finance]
Catalyst Pharmaceuticals, Inc. (CPRX)
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.catalystpharma.com
Company Research
Source: Yahoo! Finance
Pratteln, Switzerland, October 9, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Biomedica for the distribution of AGAMREE® (vamorolone) in Russia, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. Under the terms of the agreement, Santhera will receive a percentage of net sales, in line with previous distribution agreements, with sales expected to begin in Q1 2026. This collaboration will enable access to AGAMREE for DMD patients across the country, facilitated through regional and national managed access programs. There are approximately 1,400 patients living with DMD in Russia [1]. Dario Eklund, Chief Executive Officer of Santhera, said: “This agreement will enable more children to access this important DMD treatment, and is the latest in a series of global agreements secured in 2025. We look forward to working closely with Biomedica in the months ahead.” Oleg Parosin, Founder and
Show less
Read more
Impact Snapshot
Event Time:
CPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CPRX alerts
High impacting Catalyst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CPRX
News
- Is There Still Value in Catalyst Pharmaceuticals After Its 540% Five Year Surge? [Yahoo! Finance]Yahoo! Finance
- Catalyst: Firdapse Cliff Deferred, But Capital Allocation Still An Issue (Upgrade) [Seeking Alpha]Seeking Alpha
- A Fresh Look at Catalyst Pharmaceuticals (CPRX) Valuation Following Recent Share Price Momentum [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual ConferenceGlobeNewswire
- Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™GlobeNewswire
CPRX
Earnings
- 11/5/25 - Beat
CPRX
Sec Filings
- 12/3/25 - Form 4
- 11/28/25 - Form 4
- 11/26/25 - Form 144
- CPRX's page on the SEC website